My watch list
my.bionity.com  
Login  

Molecular Devices and Cytena Partner collaborate in single cell printing

20-Sep-2017

Molecular Devices, LLC announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This system utilizes microfluidics-based technology and real-time image analysis to isolate single cells and provide visual documentation of monoclonality for use in cell line development.

Clonal cell line development has been receiving increasing focus and investment as a method for producing targeted therapeutics.  As a part of the development process, cells producing high amounts of the antibody of interest need to be selectively isolated to be able to move them forward for additional screening. The CloneSelect SCP accelerates antibody discovery by allowing for automated isolation of single cells for a wide range of cell types.

“We are very excited about this product and how it allows us to expand our toolset in the fast-growing biotherapeutics market,” said Greg Milosevich, President at Molecular Devices.  “Our customers have been seeking ways to bring biologics and biosimilars to market more quickly, and we continue to invest in technologies that accelerate time-consuming process steps.”

Traditional methods for single cell sorting in cell line development suffer from drawbacks including low sorting efficiencies, low cell viabilities, and limited evidence of monoclonality. The CloneSelect SCP overcomes these limitations by screening for both single cells and for cell morphology immediately prior to gently depositing in the well, ensuring high cell viability. The use of sterilized, disposable cartridges also ensures the prevention of any cross-contamination or need for in-situ sterilization. During deposition, images of single cells are provided, giving customers the confidence of knowing their cell lines are monoclonal.

“This partnership will accelerate the continued growth of our business,” said Jonas Schoendube, CEO at Cytena. “We are looking forward to having additional commercial capabilities in the United States and Canada as a result of our work with Molecular Devices, and we believe that this relationship will bring superior service to our customer base.”

Facts, background information, dossiers
More about cytena
  • News

    Cytena GmbH to be acquired by CELLINK

    The owners of Cytena GmbH have agreed to sell all Cytena shares to CELLINK AB for a purchase price of 30.25M euros. Through CELLINK’s complimentary technology offering cytena sees great synergies that will support and accelerate future growth of Cytena. An extended product offering and a st ... more

    Cytena Founds Subsidiary in Taiwan

    Cytena is continuing its growth with the establishment of its subsidiary Cytena Bioprocess Solutions in Taiwan. Cytena Bioprocess Solutions is developing an innovative technology, which enables considerable reductions in time and increases in efficiency for cell line development.  "With the ... more

    Molecular Devices and life science start-up cytena expand their partnership

    Molecular Devices, LLC announced an expansion in its partnership with cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ Series in North America. Building on their success of the CloneSelect™ Single-Cell Printer™ SCP™ system, the new family evolves both the ease of use for image-ba ... more

  • Companies

    cytena GmbH

    cytena GmbH is a spin-off company of the University of Freiburg. The team provides a single-cell printer for isolation of single living cells. The single-cell printer is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate, ... more

More about Molecular Devices
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE